– USA, TX – Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company today announced the appointment of Dr. Gabriela Gruia (M.D.) to its Board of Directors.
“Dr. Gruia brings a wealth of industry knowledge to our Board of Directors. She has an impressive track record in global regulatory strategy and clinical operations, having played a leading role in development and regulatory approval of a number of well-known anti-cancer agents. We look forward to leveraging her scientific and strategic expertise as we continue to advance our ETB platform,” said Board Chairman, Dr. Barry Selick.
About Dr. Gabriela Gruia
Dr. Gruia is an oncologist with over 25 years of experience in oncology drug development, spanning cell and gene therapy, bi-specifics, biologics, immunotherapy, and small molecules. Dr. Gruia previously served as Chief Development Officer at Ichnos Sciences, where she oversaw development activities for several key functions, including Clinical Development and Clinical Operations, Regulatory Sciences, Clinical Pharmacology, Toxicology, and Biostatistics. Before Ichnos Sciences, Dr. Gruia was SVP and Global Head of Regulatory Affairs for Novartis Oncology, where she led the world-class oncology regulatory affairs organization and oversaw all regulatory activities in close partnership with research collaborators, preclinical development, development organization, and senior management. While at Novartis, Dr. Gruia spearheaded the worldwide submission and approval of multiple new molecular entities, including Tasigna, Jakavi, Afinitor, Signifor, Zykadia, Farydak, Rydapt, Odomzo, Kisqali, Kymriah, Adakveo, and Piqray. Before that, she held oncology clinical research and development roles at Pfizer, Pharmacia, Aventis, and Rhone Poulenc Rorer.
Dr. Gruia said, “I am pleased to have the opportunity to join the Molecular Templates Board of Directors. The ETB platform is a powerful and versatile technology that has the potential to generate novel and innovative therapeutics against a range of tumors. I look forward to providing my insights as the Company advances its pipeline of promising therapeutic candidates.”
Dr. Gruia earned a doctorate in medicine from Bucharest Medical School in Romania and a Master’s in Breast Pathology and Mammography from the Rene Huguenin/Curie Institute Cancer Center in Paris, France. She completed training in oncology and hematology at Rene Descartes University in Paris, France.
About Molecular Templates
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.
For more information: https://www.mtem.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
